Australian Multidisciplinary Association for Psychedelic Practitioners

In February 2023, the Therapeutic Goods Administration (TGA) rescheduled Psylocibin and MDMA from Schedule 9 to Schedule 8. This allowed them to be legally prescribed under very strict conditions for the treatment of Treatment-Resistant Depression (TRD) and Post Traumatic Stress Disorder (PTSD). AMAPP has been formed to be the peak body for psychedelic-assisted therapy (PAT) in Australia; providing a framework for its safe, ethical, accountable and effective introduction focusing on the best client outcomes. We are in a world-first position to provide guidance at a national level for the legal use of PAT. Our trained members are from multi-disciplinary mental health backgrounds in research and clinical practice and include Doctors, Psychologists, Psychiatrists, Social Workers, Nurses, Paramedics and Therapists of different disciplines right across Australia, with extensive knowledge and experience. Our mission is to create a trusted and ethical space for Psychedelic Assisted Treatment (PAT) practitioners to thrive. By providing peer support, advocacy, educational opportunities and resources, we strengthen a movement that honours healing, integrity, and the useful role of psychedelics in helping address mental health problems and the maintenance of a healthy society. 1. Peer Support: Nurture a connected and multidisciplinary PAT community that honours both professional expertise and lived experience. Through mentorship, leadership, and a strong foundation of support, this network fosters resilience, ethical practice, and innovation, strengthening the field for both practitioners and society. 2. Advocacy: We advocate for equitable, safe, and ethical PAT by promoting awareness, access, and harm reduction for the community, supporting client rights to best-practice care, and ensuring fair policies, protections, and support for practitioners. 3. Trust: As the peak PAT body, AMAPP integrates research into real-world practice, balancing potential and risk.